2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Opioids, Women’s Health, Adverse Events, Biological Processes, Hematopoiesis, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Immunodeficiency, Infectious Diseases, Bacterial, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4676 Age-specific cumulative burden of recurrent common complications in sickle cell disease: A mean cumulative count analysis

Joseph R Wardell, MPH, Renee Hodges, BA2, Kelly Pimenta, PhD, MPH3, Qi Liu, MSc4, Janna Lipford5, Clifford Takemoto, MD6, Deepa Manwani I, MD7, Yutaka Yasui, PhD8, Nickhill Bhakta9, Jane Hankins, MD,MS10
1 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
2 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
3 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
4 University of Alberta, Edmonton, Alberta, Canada
5 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
6 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
7 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
8 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
9 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
10 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States

Background: Sickle cell disease (SCD) is characterized by diverse complications that occur and recur throughout life, contributing substantially to hospitalization, progressive organ injury, reduced quality of life, and premature mortality. However, their cumulative burden remains poorly characterized because conventional time-to-first-event analyses discard subsequent episodes and inconsistent outcome definitions limit comparisons across studies. The Sickle Cell Outcome Grading System (SCOGS) provides standardized definitions and severity grades 1-5 for 53 clinically relevant SCD outcomes, enabling consistent outcome ascertainment and severity-specific reporting (Aurora, Lancet Haem 2026).

Objectives: To quantify the cumulative burden of recurrent common SCD complications and characterize their age-specific accumulation patterns using SCOGS definitions and mean cumulative count (MCC) analysis.

Methods: We analyzed participants in the prospective St. Jude Sickle Cell Clinical Research and Intervention Program (SCCRIP) birth-entry cohort, with outcomes ascertained through clinical assessments and medical record abstraction. Outcomes included acute pain crisis, acute chest syndrome (ACS), acute kidney injury (AKI), sepsis, splenic sequestration, alloimmunization, and stroke. All events, regardless of severity grade, were included in the MCC estimates. Using age as the time scale, we estimated MCCs nonparametrically, accounting for delayed entry at cohort enrollment and treating death as a terminal event. MCC represents the expected cumulative number of events per cohort member by a given age while accounting for recurrent events, right censoring, and the fact that death precludes subsequent events. Estimates were truncated at age 32.6 years, after which fewer than 10% of the cohort remained under observation. Pointwise 95% confidence intervals (CIs) were estimated from 1,000 bootstrap replicates.

Results: Among 1,583 participants, 61.2% had HbSS/HbSβ⁰, 35.0% had HbSC/HbSβ⁺, 51.5% were female, and 56.2% were aged ≤18 years as of December 31, 2023. Overall, 63.3% received hydroxyurea, and 19.0% received chronic transfusion therapy. Cumulative burden varied more than 1,000-fold across complications. By age 32.6 years, acute pain had the greatest cumulative burden (MCC, 22.0; 95% CI, 17.7–26.5), followed by AKI (MCC, 10.54; 95% CI, 9.18–12.01) and ACS (MCC, 1.92; 95% CI, 1.66–2.19). These estimates corresponded to approximately 22 acute pain episodes, 11 AKI episodes, and 2 ACS episodes per cohort member by age 32.6 years. By age 32.6 years, sepsis (MCC, 0.334; 95% CI, 0.268–0.414) and alloimmunization (MCC, 0.283; 95% CI, 0.173–0.414) corresponded to cumulative burdens of 33.4 and 28.3 events per 100 cohort members, respectively. At the same age, splenic sequestration (MCC, 0.028; 95% CI, 0.019–0.038) and stroke (MCC, 0.020; 95% CI, 0.009–0.035) corresponded to 2.8 and 2.0 events per 100 cohort members, respectively. Splenic sequestration accumulated almost entirely during early childhood, whereas alloimmunization accumulated through adolescence and young adulthood before plateauing near age 24 years. In contrast, acute pain, AKI, and ACS continued to accumulate throughout follow-up without plateauing. Acute pain burden increased sharply after age 18 years, rising from an MCC of approximately 5 at age 18 years to 22.0 at age 32.6 years; approximately three-quarters of the cumulative pain burden accrued after age 18 years.

Conclusions: Combining standardized SCOGS definitions with MCC analysis quantified the substantial burden of recurrent SCD morbidity not captured by time-to-first-event analyses. Distinct age-specific patterns identify important windows for prevention and intervention, including early childhood for splenic sequestration and adolescence through young adulthood for alloimmunization, while the persistent accumulation of acute pain, AKI, and ACS highlights substantial ongoing morbidity into adulthood. The relatively low stroke burden may reflect the use of disease-modifying and preventive therapies, including hydroxyurea and chronic transfusion therapy. By incorporating all recurrent events while treating death as a terminal event, MCC provides a more complete characterization of disease burden than conventional time-to-first-event analyses and may serve as a useful endpoint in observational studies and clinical trials designed to reduce cumulative SCD morbidity.

Joseph R Wardell, MPH: No relevant conflicts of interest to declare.